Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 7.4% – What’s Next?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares traded down 7.4% during trading on Monday . The company traded as low as $23.38 and last traded at $23.48. Approximately 82,037 shares were traded during trading, a decline of 77% from the average daily volume of 362,017 shares. The stock had previously closed at $25.36.

Analysts Set New Price Targets

A number of research firms recently commented on DMRA. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Wedbush reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. HC Wainwright initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Damora Therapeutics, Inc. Common Stock Price Performance

The company’s 50-day simple moving average is $23.78 and its 200-day simple moving average is $25.52. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -4.28 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Research analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of DMRA. Janus Henderson Group PLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $40,000. Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $266,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Sigma Planning Corp acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $334,000. Finally, Two Sigma Investments LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $76,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.